Product
HuMax-IL8
1 clinical trial
1 indication
Indication
Head and Neck Squamous Cell CarcinomaClinical trial
Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Cancer Patients Undergoing SurgeryStatus: Recruiting, Estimated PCD: 2024-08-01